Shares of Ardent Health, Inc. (NYSE:ARDT – Get Free Report) have been assigned a consensus recommendation of “Hold” from the fourteen analysts that are presently covering the firm, Marketbeat reports. Two research analysts have rated the stock with a sell recommendation, five have assigned a hold recommendation and seven have given a buy recommendation to the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $14.25.
Several research firms have recently commented on ARDT. Zacks Research raised shares of Ardent Health from a “strong sell” rating to a “hold” rating in a research report on Wednesday, March 25th. Leerink Partners reduced their price target on shares of Ardent Health from $16.00 to $15.00 and set an “outperform” rating on the stock in a research report on Friday, March 6th. JPMorgan Chase & Co. reduced their price target on shares of Ardent Health from $12.00 to $11.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 20th. Finally, Royal Bank Of Canada reduced their price target on shares of Ardent Health from $14.00 to $13.00 and set an “outperform” rating on the stock in a research report on Monday, March 9th.
Read Our Latest Stock Report on Ardent Health
Ardent Health Trading Up 1.5%
Ardent Health (NYSE:ARDT – Get Free Report) last released its quarterly earnings results on Tuesday, May 5th. The company reported $0.28 EPS for the quarter, beating the consensus estimate of $0.18 by $0.10. The firm had revenue of $1.60 billion for the quarter, compared to analyst estimates of $1.58 billion. Ardent Health had a net margin of 2.15% and a return on equity of 14.30%. Ardent Health has set its FY 2026 guidance at 0.900-1.270 EPS. Analysts expect that Ardent Health will post 1.11 EPS for the current fiscal year.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently modified their holdings of ARDT. Goldentree Asset Management LP raised its holdings in shares of Ardent Health by 99.7% in the 4th quarter. Goldentree Asset Management LP now owns 2,303,113 shares of the company’s stock valued at $20,302,000 after buying an additional 1,150,000 shares during the period. Goldman Sachs Group Inc. raised its holdings in shares of Ardent Health by 1,684.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 767,862 shares of the company’s stock valued at $10,558,000 after buying an additional 724,841 shares during the period. Ameriprise Financial Inc. raised its holdings in shares of Ardent Health by 75.6% in the 2nd quarter. Ameriprise Financial Inc. now owns 1,634,822 shares of the company’s stock valued at $22,332,000 after buying an additional 703,739 shares during the period. Bridgeway Capital Management LLC raised its holdings in shares of Ardent Health by 108.2% in the 4th quarter. Bridgeway Capital Management LLC now owns 946,571 shares of the company’s stock valued at $8,358,000 after buying an additional 491,961 shares during the period. Finally, Hotchkis & Wiley Capital Management LLC purchased a new stake in shares of Ardent Health in the 3rd quarter valued at $6,377,000.
Ardent Health Company Profile
Ardent Health, listed on the New York Stock Exchange under the ticker ARDT, is a healthcare delivery company focused on acquiring, developing and managing acute care hospitals and complementary outpatient facilities across the United States. The company’s integrated platform encompasses both inpatient and outpatient services, designed to provide end-to-end care solutions and address the full continuum of patient needs.
Through its network, Ardent Health operates general hospitals, emergency departments, ambulatory surgery centers, urgent care clinics, rehabilitation and post-acute care facilities.
See Also
Receive News & Ratings for Ardent Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ardent Health and related companies with MarketBeat.com's FREE daily email newsletter.
